Supported by
The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive and consumer-focused market.
By Eshe Nelson
Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss and diabetes drugs, announced on Wednesday that it would cut 11 percent of its global work force as it sought to lower costs and rejuvenate the company’s growth prospects.
The company will shed about 9,000 jobs, 5,000 of which will be in Denmark, and expects the decision will save 8 billion Danish kroner ($1.3 billion) a year by the end of 2026.
